e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Quality of life and survival after pancreatic resection– A cross-sectional study (#323)

Clare Toms 1 2 , Daniel Steffens 1 2 , David Yeo 1 2 3 4 , Carlo Pulitano 2 3 4 , Charbel Sandroussi 1 2 3 4
  1. Surgical Outcomes Research Centre (SOuRCe), Camperdown, NSW, Australia
  2. Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney , Australia
  3. Institute of Academic Surgery, Sydney, NSW, Australia
  4. Department of Upper Gastrointestinal and Hepatobiliary surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia


To investigate quality of life (QOL) trajectories and survival following pancreatic resection for malignant or benign disease.


Consecutive patients undergoing pancreatic resection between Apr-2014 and Apr-2019 at six major hospitals in Sydney, Australia were included. The main outcome was QOL assessed with the Short Form 36 (SF-36v2) and expressed as mental (MCS) and physical component scores (PCS) (/100, 0 worst QOL) and the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep) (/180, 0 worst QOL). Time from surgery was categorised into 3-11, 12-23, 24-35, and 36-62 months post-surgery for analysis of QOL outcomes. The survival of these patients was analysed using Kaplan-Meier and Log-rank tests.


A total of 278 patients underwent surgery. Mean (SD) age was 65.0 (13.2) years and 51% (n=141) were male. Malignancy was the indication for surgery in 188 patients (68%), of which 169 (61%)underwent pancreaticoduodenectomy. 205 patients were eligible and invited to participate in the QOL study, of which 128 (62%) responded.

No difference in the PCS and total FACT-Hep score was observed for the studied period. A significant improvement in the MCS was observed between 3-11 months and 12-23 months postoperatively (MD: 9.4; 95%CI: 1.1, 17.1) and 3-11 months and 36-62 months (MD: 9.4; 95%CI: 1.1, 17.1).

The median overall survival was 45.8 months (95%CI: 42.4, 49.1). A significant difference in median survival curves was observed according to malignancy 40.3 months (95%CI: 36.4, 44.2), premalignancy 54.3 months (95%CI: 47.5, 61.0), and benign disease 41.3 months (95%CI: 37.9, 44.9).


MCS improved significantly between 3-11 months and 12-23 months and 3-11 months and 36-62  months, with no further significant changes in QOL outcomes observed. A significant difference in median survival curves was observed for malignant, premalignant, and benign disease.